Variable | Univariate HR (95% CI) | P | Multivariate HR (95% CI) | p |
---|---|---|---|---|
Recurrence | ||||
Gender | 1.338 (0.817–2.191) | 0.247 | ||
Age | 1.497 (0.658–3.403) | 0.336 | ||
Multifocality | 1.526 (0.642–3.629) | 0.339 | ||
Size | 1.869 (0.850–4.108) | 0.120 | 2.668 (1.146–6.215) | 0.023 |
Grade | 0.443 (0.190–1.033) | 0.060 | 1.243 (0.232–6.664) | 0.800 |
Risk | ||||
Lowa | ||||
Immediate | 1.934 (0.696–5.371) | 0.206 | 2.762 (0.461–16.543) | 0.266 |
High | 3.019 (1.186–7.685) | 0.020 | 3.632 (0.535–24.633) | 0.187 |
reTURBT | 0.441 (0.182–1.068) | 0.070 | 0.667 (0.134–3.313) | 0.620 |
Gemcitabine vs Epirubicin or Pirarubicin | 0.159 (0.066–0.382) | 0.000 | 0.179 (0.072–0.447) | < 0.001 |
Progression | ||||
Gender | 1.266 (0.583–2.747) | 0.552 | ||
Age | 0.765 (0.221–2.644) | 0.672 | ||
Multifocality | 4.063 (0.819–20.143) | 0.086 | 4.168 (0.827–21.000) | 0.084 |
Size | 2.188 (0.195–24.519) | 0.525 | ||
Grade | 1.333 (0.376–4.727) | 0.657 | ||
Risk | ||||
Lowa | ||||
Immediate | 0.993 (0.181–5.432) | 0.993 | ||
High | 1.945 (0.486–7.780) | 0.347 | ||
reTURBT | 0.323 (0.068–1.521) | 0.153 | 0.278 (0.055–1.394) | 0.120 |
Gemcitabine vs Epirubicin or Pirarubicin | 0.110 (0.023–0.518) | 0.005 | 0.155 (0.031–0.781) | 0.024 |
Treatment failure | ||||
Gender | 0.447 (0.128–1.561) | 0.207 | ||
Age | 2.094 (0.736–5.960) | 0.166 | 2.244 (0.591–8.527) | 0.235 |
Multifocality | 2.156 (0.739–6.290) | 0.160 | 1.447 (0.479–4.368) | 0.512 |
Size | 0.897 (0.314–2.562) | 0.840 | ||
Grade | 1.485 (0.491–4.485) | 0.484 | ||
Risk | ||||
Lowa | ||||
Immediate | 1.315 (0.443–3.906) | 0.622 | ||
High | 0.455 (0.099–2.080) | 0.310 | ||
reTURBT | 1.429 (0.537–3.804) | 0.475 | ||
Gemcitabine vs Epirubicin or Pirarubicin | 0.377 (0.140–1.018) | 0.054 | 0.248 (0.074–0.830) | 0.024 |